Correlate Energy Corp. (CIPI) Bolsters its C-Suite Team and Board of Directors with Three New Appointments; Optimistic About Continued Growth and Success

 

• Correlate Energy, a publicly traded distributed energy solutions company, has announced one addition to its C-suite team and two additions to its board of directors
• Johan Themaat will serve as the company’s new CFO, while Dr. Christine Gulbranson and Alina Zagaytova will serve on the board of directors
• Correlate’s management is confident that these appointments will play a pivotal role in the company’s continued success, as well as its commitment to sustainable energy solutions
• It is also confident that they will help assert the company’s position as a leader in the industry, even as it works toward providing clean energy solutions

Correlate Energy (OTCQB: CIPI), a publicly traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation, has announced notable additions to its c-suite team, as well as its board of directors. This follows the successful close of the 2023 calendar year and the commencement of what is set to be the company’s biggest year yet. Its management is confident that these appointments will play a pivotal role in Correlate’s continued success and its commitment to sustainable energy solutions (https://ibn.fm/q6mGT).

Johan Themaat will serve as Correlate’s new CFO. He will lend his years of experience, having held key positions and executed integral roles at prominent companies that include, but are not limited to, Mission Energy, NGL Energy Partners, and RBS, among others. Throughout his professional career, Themaat has demonstrated his expertise in guiding companies through strategic financial incentives, fetes that make him such a valuable addition to Correlate’s leadership.

Correlate also appointed Dr. Christine Gulbranson and Alina Zagaytova to its board of directors, additions that its management is confident will contribute to the strategic vision and growth of the company. Dr. Christine, the Founder of Nova Global Ventures, will lend her knowledge and expertise on AI and disruptive technology while also providing guidance and insight into strategic partnerships, AI-powered consumer technology, and commerce. This is further compounded by her commitment to innovation and her overall business acumen that has seen her oversee a $100 billion + technology investment portfolio, a $37 billion operations budget, and  $1 billion + in sales, having served as a Chief Innovation Officer for the University of California System.

Ms. Alina Zagaytova will also lend her expertise in renewable energy, having served on the boards of two clean energy companies – Clean Energy Collective, LLC and Younicos AG. She will also offer guidance on legal matters, given her background as a legal and corporate strategist with an impressive track record of closing over 50 transactions. In addition, her impeccable leadership skills, as evidenced by her recent role as General Counsel, Corporate Secretary, and Chief Compliance Officer of Redwood Materials, Inc., a lithium-ion battery materials company, will also be quite valuable at Correlate.

Correlate’s management is confident that these appointments will be integral to the company’s success going forward. It is also confident that the appointments will help assert the company’s position as a leader in the industry, even as it seeks to finance, develop, and profitably sell localized clean energy solutions and microgrids to industrial, commercial, and residential customers.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.correlate.energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlate.energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study

 

• Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide
• The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single dose
• DehydraTECH GLP-1 processed semaglutide also proved to be better tolerated than the control, with the latter resulting in some cases of moderate nausea and diarrhea
• This milestone brings Lexaria closer to tapping into the diabetes and weight loss treatment market and sets the company up for what is expected to be its best year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The drug is approved by the Food and Drug Administration (“FDA”), given its role in promoting insulin production in the body, which ultimately reduces blood glucose (https://ibn.fm/UGKtr).

Most notable from its pilot study was the improved delivery of semaglutide to the bloodstream, which significantly improved blood sugar control. For one, in just 20 minutes after oral administration, the DehydraTECH GLP-1 blood semaglutide level was about 261% higher than that of the Control, a statistic that reflected the technology’s ability to deliver drugs into the bloodstream faster. In addition, 24 hours after the ingestion of a single dose, the DehydraTECH GLP-1 blood semaglutide levels were approximately 44% higher than the Control levels.

The Rybelsus control witnessed a large increase in blood-glucose levels after eating a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark. But the DehydraTECH processed Rybelsus continued to reduce blood glucose even after eating. In addition, even as long as 24 hours after dose administration, Lexaria’s DehydraTECH GLP-1 showed a 5.01% reduction in blood glucose level relative to baseline, an indicator of greater efficacy in achieving blood glucose reduction, and helping attenuate the postprandial spikes in blood glucose experienced in the control group.

DehydraTECH GLP-1 processed semaglutide also proved better tolerated than the Rybelsus tablets, with the latter resulting in instances of moderate nausea and moderate diarrhea.

Lexaria first announced its intention to explore DehydraTECH’s effectiveness on GLP-1 drugs in September 2023. From the beginning, the goal was to achieve superior pharmacokinetic (“PK”) performance with the technology with reduced side effects and enhanced health benefits. With the just-released final results, Lexaria has achieved these objectives and more, ultimately setting itself up for additional human and animal studies in the 2024 calendar year.

This milestone brings Lexaria closer to tapping into the diabetes treatment market, valued at $92.97 billion in 2023 and projected to reach $118.77 billion by 2028 (https://ibn.fm/lsAji). It also marks an excellent start to the new year 2024, propping the company up for what will be its best year yet. Lexaria is already preparing for other human and animal studies to continue, details of which will be shared in the coming weeks.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) ‘Ready to Challenge’ with New Five RS SUV, Reports ‘Road Track’ Article

 Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its Mullen Five RS were spotlighted in a recent “Road Track” article. The article noted that the sporty new model, which was revealed at CES 2024, is “ready to challenge Tesla and Lucid in the performance EV space. . . . Known as the Mullen Five RS, this electric crossover promises to bring over 1000 hp and a sub-2.0-second 0-60 mph sprint.” The article provided a background look at Mullen, which was incorporated in 2014 and comprises pieces of Coda Motor Cars and Mullen Motors. Calling the Five RS “a hotter variant of the brand’s Five SUV,” the article reported that the EV is powered by a 100-kWh battery pack which feeds a pair of electric motors to provide all-wheel drive and more than 1000 horsepower and 850-pound feet of torque. The design includes a two-speed sequential transmission sitting with either motor, which Mullen says will help the sleek SUV hit 60 mph in less than two seconds. In addition, the article reported that a set of either 21- or 22-inch wheels will cover carbon Brembo brakes at all four corners and will come wrapped in performance rubber. Mullen is working to reach 300 miles per charge, the article stated.

To view the full article, visit https://ibn.fm/OtB4S

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover; the Mullen-GO Commercial Urban Delivery EV; the Mullen commercial class 1–3 EVs; and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and class 4–6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all Electric Last Mile Solutions (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program

 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies. In a recent human pilot study with seven volunteers, Lexaria demonstrated superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The positive results were sufficient to encourage a much more thorough and expanded investigation. The objective of the new planned studies, as detailed in the announcement, is to help determine the commercial applicability of DehydraTECH to at least three GLP-1 drugs (semaglutide, liraglutide and tirzepatide), which together produced billions in revenue to their owners as reported in recent financial statements.

To view the full press release, visit https://ibn.fm/MuCaC

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Releases Third-Quarter 2024 Financial Report

 FingerMotion (NASDAQ: FNGR), a mobile services and data company, is reporting on its financial results for the third quarter of fiscal 2024, the period ended Nov. 30, 2023. Numbers to note from the report include quarterly revenue of $6.14 million, which includes the company’s SMS & MMS, Telecommunications Products & Services businesses as well as Big Data, totaled $5.26 million, or 46% decrease, compared to Q3 2023; a quarterly decrease in Telecommunications Products & Services business revenue of $4.22 million or 41% compared to Q3 2023; quarterly Big Data revenue of $.01 million compared to $.19 million in Q3 2023; quarterly SMS & MMS business revenue of $.01 million compared to $.87 million in Q3 2023; quarterly cost of revenue of $5.50 million, which was down 48%, or $5.04 million, from Q3 2023; a gross profit of $.64 million, down $.22 million, or 26%, when compared to Q3 2023, with a quarterly loss of $1.94 million, which was a decrease of $0.58 million compared to Q3 2023. The report also noted a basic and diluted loss per share of $0.04 versus a loss per share of $0.06 for Q3 2023. The reported also noted that as of Nov. 30, 2023, the company had $1,934,565 in cash and cash equivalents, a working capital surplus of $12,510,848 and a positive shareholders equity of $12,636,828 with assets totaling $17.57 million, current liabilities totaling $4.92 million and total liabilities reaching $4.92 million. “The numbers do not reflect the optimism that management sees going forward,” said FingerMotion CEO Martin Shen in the press release. “We were looking for positive cash flow from our diversification into new business segments by the end of the quarter but missed the cutoff. Exciting new business segments are underway in the current quarter that could improve revenues, margins, and get us close to our goal of profitability. We are building this business for the long term and innovate our way out of market challenges.”

To view the full press release, visit https://ibn.fm/rDVtg

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN